Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: J Immunol. 2011 Nov 23;188(1):57–67. doi: 10.4049/jimmunol.1100783

Figure 8. DEX-specific ASCs in the bone marrow are resistant to anti-CD20 mediated depletion and maintain serum anti-DEX antibody titers.

Figure 8

A protocol similar to that described in Figure 7A was used with the exception that mice received anti-CD20 or IgG2a controls at days 37, 44 and 51 after injection with E. cloacae strain MK7. (A) Total cell numbers of DEX+ λ+ CD138+ cells in the spleen, and bone marrow, and DEX+ λ+ B cells in the peritoneal cavity as determined by flow cytometry. (B) Total numbers of DEX+ λ+ ASCs in the spleen and bone marrow as determined by ELISpot assay. (C) Titers of serum DEX+ λ+ antibodies were measured at the indicated time points after immunization with E. cloacae strain MK7. Closed circles: Rat IgG2a control antibody-treated mice; open circles: anti-CD20 antibody-treated mice. Data shown was calculated from 2 independent experiments (n= 5 mice per group).